Danaher reported Q1 results slightly above expectations, with 0.5% core revenue growth and EPS beat, driven by bioprocessing strength and better life sciences trends. Management raised full-year EPS guidance while maintaining core revenue growth 3-6%, citing fading headwinds in H2. The pending Masimo acquisition remains on track with synergy targets. Q1 core revenue +0.5% YoY; ex-respiratory, rest of business grew 3%.
Danaher reported Q1 results slightly above expectations, with 0.5% core revenue growth and EPS beat, driven by bioprocessing strength and better life sciences trends. Management raised full-year EPS guidance while maintaining core revenue growth 3-6%, citing fading headwinds in H2. The pending Masimo acquisition remains on track with synergy targets. Q1 core revenue +0.5% YoY; ex-respiratory, rest of business grew 3%.
Management expressed optimism about portfolio momentum, highlighted encouraging order trends and share gains, and raised EPS guidance despite a softer respiratory season.
Guidance tone
Adjusted EPS $2.06, +9.5% YoY, above guidance.
Management views AI as a growth accelerator for the pharma and biotech industry, both near-term (through autonomous science and biologic models requiring automation, instruments, and reagents) and long-term (by compressing development cycles and improving yields, driving demand…
Management views AI as a growth accelerator for the pharma and biotech industry, both near-term (through autonomous science and biologic models requiring automation, instruments, and reagents) and long-term (by compressing development cycles and improving yields, driving demand for life science and bioprocessing solutions). They also link AI to internal productivity via 'AI-enabled DBS,' but provi
Bioprocessing equipment orders grow >30% year-over-year, first positive quarter in two years.. Management expressed optimism about portfolio momentum, highlighted encouraging order trends and share gains, and raised EPS guidance despite a softer respiratory season.
Management notes that bioprocessing equipment investment has been muted, but they are encouraged by a >30% year-over-year increase in equipment orders (first positive quarter in nearly two years), and believe they are in the early stages of a multi-year investment cycle, with brownfield projects today and larger greenfield investments expected to follow. They also mention reshoring as a driver of
Management expressed optimism about portfolio momentum, highlighted encouraging order trends and share gains, and raised EPS guidance despite a softer respiratory season.
“And while we have limited direct revenue or supply chain exposure to the region, we're mindful of potential pressures from a sustained conflict.”
“orders growth of more than 30%, marking the first quarter of year-over-year equipment order growth in nearly two years.”
“volume growth in China was slightly better than our expectations, an encouraging indicator for future demand and growth as we move past the most significant year-over-year impacts from current policy headwinds.”
“We think AI is going to be a growth accelerator for the pharma and biotech industry, both in the near and in the long term.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $8.35–$8.55 | $8.45 | RAISED |
| Op margin | FY2026 Q2 | 26.5% | 26.5% | GUIDED |
| 제시 시점 | 지표 | 목표 기간 | 가이던스 | 실제 | 결과 |
|---|---|---|---|---|---|
| FY2025 Q4 | Op margin | FY2026 Q1 | 28.5% | 22.58% | Missed |
| FY2025 Q3 | EPS | FY2025 | $7.70–$7.80 | $7.80 | Met / beat |
Danaher expects Masimo’s financial profile to improve under DBS, with confirmed cost and revenue synergy targets, indicating confidence in value creation post-close.
“We expect Massimo to be accretive to adjusted diluted net earnings for common share in the first full year post acquisition and to deliver high single digit return on invested capital by the fifth full year of our ownership.”
… over a decade and believe the company is well positioned with its trusted brand, differentiated technology, and attractive financial profile. Looking ahead, we believe there are clear opportunities to run the same playbook that has driven value creation across our portfolio for many years, leveraging DBS to drive growth and expand margins while further strengthening our value proposition with customers. We expect Massimo to be accretive to adjusted diluted net earnings for common share in the first full year post acquisition and to deliver high single digit return on invested capital by the fifth full year of our ownership. The transaction remains subject to customary closing conditions, including regulatory approvals, and we look forward to welcoming the talented Massimo team to Danaher later this year. Now, alongside M&A, we made significant progress on organic growth initiatives across Danaher, including new product introductions and strategic partnerships. These efforts are strengthening our competitive positioning while helping customers improve quality and yield, reduce costs, and accelerate the delivery of life-changing therapies and diagnostics. So let me highlight a few …